462 related articles for article (PubMed ID: 32810905)
1. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
[TBL] [Abstract][Full Text] [Related]
2. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
[TBL] [Abstract][Full Text] [Related]
3. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.
Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ;
Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816
[TBL] [Abstract][Full Text] [Related]
4. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
Martin NK; Boerekamps A; Hill AM; Rijnders BJA
J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
[TBL] [Abstract][Full Text] [Related]
5. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV
Curr HIV/AIDS Rep; 2017 Jun; 14(3):110-121. PubMed ID: 28432579
[TBL] [Abstract][Full Text] [Related]
6. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
[TBL] [Abstract][Full Text] [Related]
7. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
8. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
[TBL] [Abstract][Full Text] [Related]
9. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
10. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
11. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
[TBL] [Abstract][Full Text] [Related]
12. Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study.
Marshall AD; Martinello M; Treloar C; Matthews GV
Int J Drug Policy; 2022 Nov; 109():103828. PubMed ID: 35994937
[TBL] [Abstract][Full Text] [Related]
13. Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates.
Chromy D; Bauer D; Simbrunner B; Jachs M; Hartl L; Schwabl P; Binter T; Steininger L; Schwarz C; Rieger A; Grabmeier-Pfistershammer K; Trauner M; Ferenci P; Peck-Radosavljevic M; Mandorfer M; Reiberger T
Infect Dis (Lond); 2023 Mar; 55(3):189-198. PubMed ID: 36484317
[TBL] [Abstract][Full Text] [Related]
14. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
15. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
[TBL] [Abstract][Full Text] [Related]
16. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression.
Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV
Lancet HIV; 2022 Jun; 9(6):e414-e427. PubMed ID: 35659336
[TBL] [Abstract][Full Text] [Related]
17. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.
Taylor LE; Swan T; Matthews GV
Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S118-24. PubMed ID: 23884059
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era.
Falade-Nwulia O; Gicquelais RE; Astemborski J; McCormick SD; Kirk G; Sulkowski M; Thomas DL; Mehta SH
Liver Int; 2020 Oct; 40(10):2407-2416. PubMed ID: 32770638
[TBL] [Abstract][Full Text] [Related]
19. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
[TBL] [Abstract][Full Text] [Related]
20. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
